Tag: Controlled Substances

Study: Racial, insurance disparities persist in access to buprenorphine after opioid-related events

JAMA (healthcare publication) Network logo

Editor's Note Black and Hispanic patients remain significantly less likely than White patients to receive buprenorphine after an opioid-related health care event, according research published June 26 in JAMA Network Open. Patients with Medicaid or Medicare Advantage also had higher odds of receiving buprenorphine than those with commercial insurance. The…

Read More

By: Matt Danford
July 2, 2025
Share

Painkiller without opioid risks shows potential in animal trials

Editor's Note An experimental compound developed at Duke University School of Medicine provides strong pain relief without the side effects or addiction potential of opioids, according to a May 19 announcement from the university. Known as SBI-810, the drug targets a specific receptor in the nervous system and uses a…

Read More

By: Matt Danford
June 3, 2025
Share

Prepare for DEA inspections, controlled substances oversight

The headlines are attention grabbing: hospitals forced to pay millions of dollars after employees were found to have stolen opioids and other controlled substances. After being discovered and investigated by the Drug Enforcement Agency (DEA), the agents uncovered a number of issues: poor record-keeping, inventory, tracking, and other failures that…

Read More

By: Brita Belli
February 22, 2023
Share

Session: Proper Tactics to Prepare for a DEA Inspection

Editor's Note “Is your OR ready for a DEA [Drug Enforcement Administration] inspection?” was the question Dennis Wichern, MBA, partner at Prescription Drug Consulting, asked attendees of this breakout session. As a retired DEA agent, Wichern discussed the ways the DEA has been involved in the medical field, specifically pertaining…

Read More

By: Bridget Brown
October 19, 2022
Share

Join our community

Learn More
Video Spotlight
Live chat by BoldChat